. Plasma levels of anti-IL-17A antibody levels in anti-IL-17A antibody-and isotype control-treated mice at day 28 of treatment (n=10). M. tuberculosis infected C57BL/6 mice (H37Rv, 1000 CFU i.n.) were treated once per week with anti-mouse IL-17A antibody 500 µg per mouse (20 mg/kg i.p.), and isotype control antibody, starting 1 day before the infection. Supplementary Fig. S3 . Neutralizing IL-17A or IL-17F does not compromise host response to early phase of M. tuberculosis infection, in contrast to TNFa neutralization. M. tuberculosis infected C57BL/6 mice (H37Rv, 1000 CFU i.n.) were treated once per week with anti-mouse IL-17A or IL-17F antibodies (20 mg/kg i.p.), anti-mouse TNFα antibody (10 mg/kg), respective isotype control antibodies, or vehicle, starting 1 day before the infection, and monitored for body weight. Lung pathology was assessed on day 28. Lungs of TNFα-deficient mice with large, confluent nodules are included for comparison. Microscopic examination showing extensive inflammation and necrosis in lungs of infected TNFα-deficient mice or anti-TNFα antibody treated mice (Left: haematoxylin and eosin, magnification x 50) as well as numerous acid-fast bacilli (Right: Ziehl-Nielson, magnification x 1000). 
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